Business Context and Reporting Period
Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: BioCryst is a biotechnology company utilizing structure-based drug design to develop small-molecule pharmaceuticals for cancer, viral infections, and autoimmune diseases. The company has no commercial products and relies on collaborative agreements and government contracts for revenue.
Key Financial Metrics
| Metric | 2007 | 2006 |
|---|---|---|
| Total Revenues | $71.2 million | $6.2 million |
| Research & Development Expenses | $94.1 million | $47.1 million |
| General & Administrative Expenses | $9.5 million | $6.1 million |
| Net Loss | $(29.1) million | $(43.6) million |
| Net Loss Per Share (Basic & Diluted) | $(0.89) | $(1.50) |
| Cash, Cash Equivalents & Securities | $85.0 million | $46.2 million |
| Accumulated Deficit | $(224.5) million | $(195.5) million |
Liquidity: As of December 31, 2007, the company held $85.0 million in cash and marketable securities. The company estimates a net cash burn rate of approximately $2.2 million per month for 2007 and projects 2008 net cash use to be between $25 million and $30 million.
Material Changes vs. Prior Period
- Revenue Surge: Total revenues increased 1,046% to $71.2 million, primarily driven by a $102.6 million, four-year contract with the U.S. Department of Health and Human Services (HHS) for the development of peramivir. Revenue from HHS totaled $55.4 million in 2007.
- R&D Expense Increase: R&D expenses doubled to $94.1 million due to expanded clinical and manufacturing costs for peramivir and forodesine HCl, increased personnel costs, and the recognition of $2.3 million in pre-contract costs related to the HHS agreement.
- Financing Activity: In August 2007, the company completed a $65.3 million private placement of common stock and warrants, significantly boosting cash reserves.
- Improved Loss Position: Despite higher expenses, the net loss narrowed to $29.1 million from $43.6 million in 2006 due to the substantial increase in collaborative revenue.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Peramivir (Influenza): The company announced in January 2008 that development costs for peramivir would exceed the original $102.6 million HHS contract due to changes in the development plan. HHS agreed to fund specific elements (Phase II i.v. and i.m. studies, manufacturing, toxicology) but costs outside approved limits are the company's responsibility. The company decided not to pursue the Phase III pivotal program for intramuscular peramivir in the current flu season, opting instead for a new Phase II trial evaluating higher doses.
- Forodesine HCl (Oncology): A pivotal Phase IIb trial for Cutaneous T-cell Lymphoma (CTCL) is ongoing under a Special Protocol Assessment (SPA) with the FDA. However, the Phase IIb trial for T-cell Acute Lymphoblastic Leukemia (T-ALL) was terminated in December 2007 due to stability issues with the intravenous formulation.
- BCX-4208 (Autoimmune): Partner Roche initiated a Phase IIa trial for psoriasis in late 2007.
Risks and Contingencies
- HHS Contract Risk: The company's financial condition is heavily dependent on HHS reimbursement. Delays, cost disallowances, or contract termination by HHS would have a significant negative impact on cash flow.
- Dispute with Mundipharma: The company is in a dispute with partner Mundipharma regarding contractual obligations for manufacturing and development costs of forodesine HCl. The maximum potential exposure is estimated at $5 million, though no amount has been accrued.
- Profitability: The company has incurred substantial losses since inception and expects to continue incurring losses. It has no commercial products and relies on future collaborations or product sales to achieve profitability.
Investor Verification Checklist
- HHS Contract Status: Verify the current status of the $102.6 million HHS contract, specifically regarding the funding of revised development plans and any potential cost overruns the company must self-fund.
- Peramivir Clinical Data: Review the results of the Phase II intramuscular trial and the rationale for the new Phase II trial design, as the primary endpoint was not statistically significant in the previous study.
- Forodesine HCl Trial Progress: Monitor enrollment and interim data from the pivotal CTCL trial, given the termination of the T-ALL program.
- Mundipharma Dispute Resolution: Track the resolution of the $5 million cost dispute with Mundipharma to assess potential liability.
- Cash Burn Rate: Monitor quarterly cash burn against the projected $25-$30 million usage for 2008 to determine the runway for operations without additional financing.